Details

Autor(en) / Beteiligte

• de Almeida, Valéria
• Alexandrino, Guilherme L.
• Aquino, Adriano
• Gomes, Alexandre F.
• Murgu, Michael
• Dobrowolny, Henrik
• Guest, Paul C.
• Steiner, Johann
• Martins-de-Souza, Daniel

Titel

Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients

Ist Teil von

• Progress in neuro-psychopharmacology & biological psychiatry, 2020-07, Vol.101, p.109945-109945, Article 109945

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Atypical antipsychotics are widely used to manage schizophrenia symptoms. However, these drugs can induce deleterious side effects, such as MetS, which are associated with an increased cardiovascular risk to patients. Lipids play a central role in this context, and changes in lipid metabolism have been implicated in schizophrenia's pathobiology. Furthermore, recent evidence suggests that lipidome changes may be related to antipsychotic treatment response. The aim of this study was to evaluate the lipidome changes in blood plasma samples of schizophrenia patients before and after 6 weeks of treatment with either risperidone, olanzapine, or quetiapine. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis showed changes in the levels of ceramides (Cer), glycerophosphatidic acids (PA), glycerophosphocholines (PC), phosphatidylethanolamines (PE), phosphatidylinositols (PI), glycerophosphoglycerols (PG), and phosphatidylserines (PS) for all treatments. However, the treatment with risperidone also affected diacylglycerides (DG), ceramide 1-phosphates (CerP), triglycerides (TG), sphingomyelins (SM), and ceramide phosphoinositols (PI-Cer). Moreover, specific lipid profiles were observed that could be used to distinguish poor and good responders to the different antipsychotics. As such, further work in this area may lead to lipid-based biomarkers that could be used to improve the clinical management of schizophrenia patients. •Changes in the lipidome are involved in the pathobiology of schizophrenia.•Antipsychotics affect the metabolism of lipids.•Dyslipidemia is observed in the antipsychotic-induced metabolic syndrome.•Specific lipid profiles can distinguish poor and good responders to the different antipsychotics.•Different classes of lipids are modulated in good and poor antipsychotic responders•Our data provide userful hints for the development of new and more effective medication.